Integration of Pharmaceutical Discovery and Development: Case Histories (Volume 11). Questo articolo non è disponibile.
Lingua: inglese
Editore: Plenum Press, 1998
- Rilegato
- Usato

Venditore Heritage
Da: Anybook.com, Lincoln, Regno UnitoAnybook.com
Venditore con 5 stelle
Venditore AbeBooks dal 22 dicembre 1999
Non disponibile
Rilegato
Condizione: Usato - Buono
EUR 26,32
Descrizione dell’articolo da parte del venditore
Volume 11. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,1150grams, ISBN:9780306457432.
Codice articolo 5558941
- Titolo
- Integration of Pharmaceutical Discovery and Development: Case Histories (Volume 11)
- Autore
- Sawyer, T K
- Editore
- Plenum Press
- Anno di pubblicazione
- 1998
- Condizione
- Good
- Rilegatura
- Rilegato
- Lingua
- inglese
- ISBN 10
- 0306457431
- ISBN 13
- 9780306457432
- Peso dell'articolo
- 1150 grammi
- Cataloghi dei venditori
- Science & Technology
In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.
"Riassunto" può appartenere a un’altra edizione di questo titolo.
Dalla quarta di copertina
In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.
"Descrizione articolo" può appartenere a un’altra edizione di questo titolo.
Risultati della ricerca per Integration of Pharmaceutical Discovery and Development: Case Histories (Volume 11)
Ci sono altre 2 copie di questo libroVisualizza tutti i risultati